Stanford researchers have developed a new vaccine helper that combines two adjuvants to improve vaccine efficacy for COVID-19 and HIV candidates. The experimental additive enhanced the effectiveness of vaccines and could be adapted for various pathogens. The new adjuvant platform, using sphere-shaped nanoparticles and toll-like receptor agonists, triggered stronger and longer-lasting immune responses compared to traditional adjuvants. Combining different adjuvants has become a growing interest in vaccine research. TLR agonists have shown promise in activating the immune system for better protection. The customizable aspect of TLR agonists could allow vaccines to be tailored for different populations, maximizing effectiveness and safety. In the future, the nanoparticle platform could be used to test different adjuvant combinations in vaccines.
Source link
The New Formula for Stronger, Longer-Lasting Vaccines
